<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Drugs Limited has informed BSE that it does not qualify as a "Large Corporate" (LC) under the SEBI framework for debt issuance as of March 31, 2026. The company cites SEBI circulars from November 2018 and October 2023 governing fund raising through debt securities. Since the company does not meet the applicability criteria for Large Corporates, the associated annual disclosure and compliance requirements under these circulars are not applicable to it. This is a regulatory clarification filing confirming the company's non-classification.
Neutral for shareholders. The company avoids enhanced disclosure obligations mandated for Large Corporates, indicating it falls below the size or other thresholds specified by SEBI for this category. No immediate impact on stock or compliance burden.